Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
Context Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response.Objective This work investigated the effects of stachydrine in CML.Mate...
Saved in:
Main Authors: | Ruixin Gu (Author), Wei Zhang (Author), Dandan Xu (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
by: Katherine E. Hodkinson, et al.
Published: (2022) -
Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing
by: Elsenoor Klaver, et al.
Published: (2019) -
Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
by: Rubin Cheng, et al.
Published: (2021) -
A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia
by: Alicia Martín Roldán, et al.
Published: (2023) -
Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023)